| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/07/2005 | US20050075403 Ambroxol for the treatment of inflammation in the pharynx |
| 04/07/2005 | US20050075402 chemical intermediates for helicobacter pylori bactericides; 4-(4-hydroxyphenyl)ethyl benzoate; antiulcer agents |
| 04/07/2005 | US20050075401 Active oxygen scavenging composition including citrulline |
| 04/07/2005 | US20050075398 Neuroprotectin D1 protects against cellular apoptosis, stroke damage, alzheimer's disease and retinal diseases |
| 04/07/2005 | US20050075397 Composition comprising at least one alkanolamide for inhibiting langerhans cells migration, and uses thereof |
| 04/07/2005 | US20050075396 Modulation of type 2 diabetes and drug delivery |
| 04/07/2005 | US20050075395 Continuous dosing regimen |
| 04/07/2005 | US20050075394 Phenethanolamine derivatives for treatment of respiratory diseases |
| 04/07/2005 | US20050075393 Cyclopropane carboxylic acid for treatment of nervous system disorders and for slowing metabolism |
| 04/07/2005 | US20050075391 Nitric oxide donor composition and method for treatment of anal disorders |
| 04/07/2005 | US20050075390 HIV protease inhibitors |
| 04/07/2005 | US20050075386 Drugs from indocasbazole derivatives |
| 04/07/2005 | US20050075385 Substituted thienoimidazoles useful for disease treatment and prevention |
| 04/07/2005 | US20050075383 Inhibitors of phophodiesterase type-IV |
| 04/07/2005 | US20050075380 Composition comprising at least one oxazolin for inhibiting langerhans cell migratio, and uses thereof |
| 04/07/2005 | US20050075378 Modulators of peroxisome proliferator activated receptors (ppar) |
| 04/07/2005 | US20050075377 Compounds for elevating plasma lipid levels with prodrugs for humans and other mammals |
| 04/07/2005 | US20050075375 Drugs as viricides for hepatitis C with carriers |
| 04/07/2005 | US20050075373 Diaryl 1,2,4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/07/2005 | US20050075371 Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| 04/07/2005 | US20050075369 Novel form of S-omeprazole |
| 04/07/2005 | US20050075367 Ester compound and medicinal use thereof |
| 04/07/2005 | US20050075365 MAP (mitogen-activated protein) kinase inhibitors; osteoarthritis, rheumatoid arthritis, anticarcinogenic or antiischemic agents; reperfusion injuries, strokes or heart attack; autoimmune, skin, cardiovascular, brain, bone, neurodegenerative, respiratory system and nervous system disorders |
| 04/07/2005 | US20050075364 Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS |
| 04/07/2005 | US20050075361 Novel ester derivatives of buprenorphine and their preparation processes, and long acting analgestic pharmaceutical compositions |
| 04/07/2005 | US20050075359 Administering coxib drug derivatives containing imidazole, pyrazole, oxazole, isoxazole, or oxazoline groups; pollakiuria or urinary incontinence; cyclooxygenase inhibitors; cerebral infarction, subarachnoid hemorrhage |
| 04/07/2005 | US20050075358 Administering a benzimidazole derivative insulin-like growth factor receptor inhibitor with metformin insulin sensitizer |
| 04/07/2005 | US20050075357 5-arylpyrimidines as anticancer agents |
| 04/07/2005 | US20050075356 E.g., N-(4-fluorobenzyl)-5,6-dihydroxy-2-[1-methyl-1-(methylamino)ethyl]pyrimidine-4-carboxamide, used for preventing, treating or delaying the onset of and infection by AIDS |
| 04/07/2005 | US20050075354 Anticarcinogenic and antiproliferative agents; diseases caused by overexpression of erbB2 |
| 04/07/2005 | US20050075353 Quinazolines and therapeutic use thereof |
| 04/07/2005 | US20050075351 4-(Azaindol-3-yl)-quinazoline, 4-(azaoxindol-3-yl)-quinazoline, or 4-(diazaindol-3-yl)-quinazoline derivatives as glycogen synthase kinase inhibitors; Alzheimer's, Parkinson's, Huntington's disease; Down syndrome, amyotrophic lateral sclerosis; neurodegenerative and brain disorders; cognition activators |
| 04/07/2005 | US20050075349 Xanthine phosphodiesterase V inhibitors |
| 04/07/2005 | US20050075346 Novel compounds |
| 04/07/2005 | US20050075345 1,2,4-Oxadiazoline-5-one or thiazolidine-2,4-dione derivatives; hypertensive, antiinflammatory, antiallergen, antiischemic, antihistamine, bronchodilator, and anticarcinogenic agents; cardiovascular, skin, gastrointestinal, and respiratory system disorders; cyclization, catalytic hydrogenation |
| 04/07/2005 | US20050075344 Melanocortin receptor agonists |
| 04/07/2005 | US20050075343 Benzimidazole derivatives as modulators of IgE |
| 04/07/2005 | US20050075341 Administering benzenesulfonamide, alkylsulfonylbenzene, benzopyran, benzothiopyran, dihydroquinoline, and/or 2-(anilino-)benzeneacetic acid derivatives |
| 04/07/2005 | US20050075339 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| 04/07/2005 | US20050075338 5-(Substituted oxazolyl- or thiazolyl-ethoxy)indaneacetic acid derivatives, used in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases |
| 04/07/2005 | US20050075337 Pharmaceutical compositions including carotenoid analogs or derivatives for the inhabition and amelioration of disease |
| 04/07/2005 | US20050075336 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity |
| 04/07/2005 | US20050075335 Pharmaceutical composition comprising n((1-n-butyl-4-piperidinyl)methyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indole-10-carboxamide or salt and process therefor comprising dry granulation |
| 04/07/2005 | US20050075334 Novel compounds |
| 04/07/2005 | US20050075332 Tricyclic compounds with antiviral activity |
| 04/07/2005 | US20050075330 Dipeptidyl peptidase inhibitors |
| 04/07/2005 | US20050075329 S-tofisopam, a prodrug or a salt thereof, free of its R enantiomer, and a carrier; may also contain one or more other anticonvulsants |
| 04/07/2005 | US20050075328 Such as (2'-methoxy-[1,1'-biphenyl]-4-yl)-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)methanone; for treatment of diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, or hemophilia |
| 04/07/2005 | US20050075323 Beta3 adrenergic receptor agonists and uses thereof |
| 04/07/2005 | US20050075322 Androgenic 7-substituted 11-halogen steroids |
| 04/07/2005 | US20050075321 Neurological disorder treatment methods |
| 04/07/2005 | US20050075319 Method of treatment using bisphosphonic acid |
| 04/07/2005 | US20050075317 Monitoring the protein concentration in plasma or tissues; treating atherosclerosis, Alzheimer's disease, macular degeneration, retinitis pigmentosa, stroke, degenerative neuropathy, multiple sclerosis, xanthoma, xanthelasma, cardiovascular disorder; tetramethyl N-(2-pyridyl)aminomethylenediphosphonate |
| 04/07/2005 | US20050075316 Therapy for ischemic-repefusion injuries; liver disorders; antiarrhythmai agents; anticancer agents; astaxanthin |
| 04/07/2005 | US20050075315 Antitumor agent |
| 04/07/2005 | US20050075314 Using pharmaceutical preparation of mucopolysaccharides having an anticoagulant activity of <100 BP units/mg for prophylactic priming or curative treatment of the cervix and the myometrium; sulfates of heparin chondroitin and dermatan and their depolymerized products |
| 04/07/2005 | US20050075313 Ophthalmic compositions containing galactomannan polymers and borate |
| 04/07/2005 | US20050075312 Antitumor inhibitors and use thereof |
| 04/07/2005 | US20050075311 Improving the health of ruminant animals, increasing milk production in lactating animals, and/or treating and controlling infective diarrhea by the oral administration of an effective amount of an indigestible oligosaccharide of gluco-oligosaccharides and/or isomalto-oligosaccharides; feed additives |
| 04/07/2005 | US20050075310 Gangliosides with a modified acyl function |
| 04/07/2005 | US20050075309 Purine nucleoside analogues for treating Flaviviridae including hepatitis C |
| 04/07/2005 | US20050075308 Methods and compositions for producing antigenic responses |
| 04/07/2005 | US20050075307 Modulation of aminopeptidase N expression |
| 04/07/2005 | US20050075305 Therapeutic compositions and methods of treating glycolipid storage related disorders |
| 04/07/2005 | US20050075301 Pharmaceutical preparation with RNA as hemostasis cofactor |
| 04/07/2005 | US20050075297 Adding water (15-79%) to a mixture of ribavirin and three excipients (binder, filler and disintegrant); drying the granulated particles and shaping; encapsulation; dustless; uniformity; greater control of dissolution rates; better flow characteristics; faster encapsulation and lower weight variations |
| 04/07/2005 | US20050075296 for extending the release times and decreasing the toxicity, by using a di-lauric acid salt of tilmicosin in an acceptable solvent, which forms a precipitate when injected into water; treating infections in dogs and cats where tilmicosin was previously too toxic |
| 04/07/2005 | US20050075295 Combination comprising combretastatin and anticancer agents |
| 04/07/2005 | US20050075294 E.g., 2-(4-Methoxybenzyl)phenyl beta -D-glucopyranoside; inhibitors of human SGLT2 (Na+/glucose cotransporter 2); prevents reabsorption of excess glucose at the kidney, promotes excreting excess glucose though the urine, and normalizes blood glucose level; hypoglycemic and antidiabetic agent; obesity |
| 04/07/2005 | US20050075282 inhibiting or preventing repression of neurotransmitter receptor gene expression upon or during an event causing brain injuries, using histone deacetylase inhibitors |
| 04/07/2005 | US20050075277 Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects |
| 04/07/2005 | US20050075276 administering peptide or non-peptide drugs that modulate the CD28 antigen inactivation of GSK-3 in lymphocytes responses against viral, bacterial, fungal or prion infections in mammals |
| 04/07/2005 | US20050075273 condensation aerosols; for treatment of pain or alcohol abuse; kits |
| 04/07/2005 | US20050075271 Crystalline beta2 adrenergic receptor agonist |
| 04/07/2005 | US20050075269 Substituted benzofuran-2-carboxamides derivatives |
| 04/07/2005 | US20050075268 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination |
| 04/07/2005 | US20050074879 Antisense oligonucleotide modulation of STAT3 expression |
| 04/07/2005 | US20050074819 Using ligand gated channel protein to identify modulators for prevention and treatment of tactile allodynia induced after nerve injury |
| 04/07/2005 | US20050074812 Molecules that home to various selected organs or tissues |
| 04/07/2005 | US20050074797 FHIT proteins and nucleic acids and methods based thereon |
| 04/07/2005 | US20050074775 assessing GST-pi expression levels in fixed or fixed and paraffin embedded tissues using primers; pharmacogenetics; determining antitumor platinum-based chemotherapeutic regimen |
| 04/07/2005 | US20050074771 For attachment to steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins; for detecting RNA in samples |
| 04/07/2005 | US20050074767 Using transcriptional activity of obesity genes as diagnostic indicator of efficacy of dietetic modulators; treating eating/weight disorders |
| 04/07/2005 | US20050074764 Using presence of point mutations in nicotinic acetylcholine receptor (nACHR) gene as diagnostic/prognosic tool in detction and treatment of indicator of cardiovascular, nervous system, vision and pain disorders |
| 04/07/2005 | US20050074743 Treating blood with solution comprising pyruvate, inosine, adenine, phosphate and an aziridino compound; for preservation and enhancing function |
| 04/07/2005 | US20050074506 Applying energy to blood brain barrier (BBB) region to break encapsulation; activating facilitator to promote passage of therapeutic and/or diagnostic agent |
| 04/07/2005 | US20050074503 Applying brilman's solution; preventing HIV/AIDS diseases, gripe and flu |
| 04/07/2005 | US20050074497 Sustained release delivery systems; contact lens shape; includes vision correction; lower dosage antiangiogenesis therapeutics; reduced local inflammation and/or adverse systemic reactions; macular degeneration; retinopathies |
| 04/07/2005 | US20050074496 Utilizing such as fucoidan to treat surgical adhesions, arthritis, psoriasis; nontoxic, reduced side effects |
| 04/07/2005 | US20050074494 Itraconazole immediate release formulation |
| 04/07/2005 | US20050074493 Once daily pain relief formulations; consistent plasma concentration; customizable profiles |
| 04/07/2005 | US20050074491 Universal controlled-release composition |
| 04/07/2005 | US20050074488 Use of vitamin Ds to down regulate the renin-angiotensin-aldosterone system |
| 04/07/2005 | US20050074487 Transdermal and topical administration of drugs using basic permeation enhancers |
| 04/07/2005 | US20050074470 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 04/07/2005 | US20050074460 Reacting a protein with a hapten (especially a luteinizing hormone releasing hormone peptides derived from E coil, or malaria derived peptides) to produce a hapten-protein conjugate, followed by reacting the hapten-protein conjugate with a polysaccharide |
| 04/07/2005 | US20050074457 Simplified, high throughput screening for identification of heat shock protein 90 ligands selective for high affinity form |
| 04/07/2005 | US20050074455 Treatment of neovascular opthalmic disease |
| 04/07/2005 | US20050074451 Synergistic combination of methotrexate with antibody to alpha 4 integrin or immunologically active antigen binding fragment |
| 04/07/2005 | US20050074447 Treatment for diabetic microvascular and macrovascular complications |